Delving into the Latest Updates on Penicillin G Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Benzylpenicillin sodium, Penicillin G sodium (USP), Crystapen

Target

PBPs

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)

Therapeutic Areas

Infectious DiseasesCardiovascular DiseasesUrogenital Diseases+ [1]

Active Indication

Endocarditis, BacterialSepsisStreptococcal Infections+ [3]

Inactive Indication-

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Inc.Seqirus Pty Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

(01 Jan 1942),

Bacterial Infections

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC16H18N2NaO4S

InChIKeyXFGIVHXZEANRAL-LQDWTQKMSA-N

CAS Registry69-57-8

The aim of this study was investigate the comparison of postoperative effects of low laser treatment and platelet-rich fibrin application on mandibular impacted third molar tooth extraction. The study included a total of 60 patients with impacted mandibular third molar. Patients were evaluated in 4 randomly separated groups. In group 1, PRF was applied to the tooth socket. In group 2, PRF was applied to the tooth socket combined with Low Laser Treatment extraorally to the extraction area for three days within surgery day In group 3, Low Laser Treatment was applied to the extraorally to the extraction area for three days within surgery day. In group 4 (control group), tradional osteomy was made. The outcome variables were pain, swelling, the number of analgesics taken, and trismus. These variables were also assessed based on first, second, third, and seventh days following the operation. All of the 4 groups patients were prescribed an 875/125 mg amoxicillin/clavulanic acid tablet twice daily for five days.

Start Date02 Jan 2024

Sponsor / Collaborator

Near East University

NCT04620746

/ CompletedPhase 4IIT

Validate an Easy to Administer Algorithm to Define Penicillin (PCN-B-lactam) Allergy Status in Sexually Transmitted Disease (STD) Clinic Outpatients

Demonstration project to implement penicillin allergy testing in STD outpatients using a questionnaire and pen allergy testing

Start Date01 Jun 2021

Sponsor / Collaborator

The Johns Hopkins University

[+4]

100 Clinical Results associated with Penicillin G Sodium

Login to view more data

100 Translational Medicine associated with Penicillin G Sodium

Login to view more data

100 Patents (Medical) associated with Penicillin G Sodium

Login to view more data

36,551

Literatures (Medical) associated with Penicillin G Sodium

01 Sep 2025·JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY

GO and CNT template impact on the WO3/Bi2S3 photocatalytic activity for pharmaceutical active compounds removal

Author: Enesca, Alexandru

A combined sol-gel and doctor blade techniques were used to obtain two types of composites.Graphene oxide (GO) and carbon nanotubes (CNT_s) were used as template in the sol-gel procedure which include two steps: WO₃ and Bi₂S₃ development.The composites crystallinity and morphol. were investigated indicating the formation of monoclinic WO₃ and orthorhombic Bi₂S₃.The GO template samples exhibit porous sponge-like morphol. with 285 m²/g SBET, while the CNT_s template samples have a granular morphol. with 294 m²/g SBET.The elemental anal. indicate that the composite components are evenly distributed through the sample.Both GO and CNT_s based samples have a predominant polar component of the surface energy which make them suitable candidate for applications in aqueous environments.The photocatalytic removal efficiency was tested in the presence penicillin G and amoxicillin (150 ppm) under UV and Vis irradiationThe highest efficiencies correspond to GO/WO₃/Bi₂S₃ which was able to remove 57.43 % PEN-G and 63.94 % AMO.The photocatalytic mechanism was investigated and described in details.

01 Jun 2025·FOOD MICROBIOLOGY

Molecular characterization of emerging multi-drug resistant Clostridium perfringens isolated from pork production chains in Korea

Article

Author: Jang, Beomsoon ; Park, Kun Taek ; Lee, Miru ; Cho, Hyeonwoo ; Kim, Yeona

Clostridium perfringens is a common cause of foodborne illnesses and is involved in human and animal gastrointestinal diseases. Surveillance of C. perfringens in the pork production chain is crucial to manage the risk of pathogen transmission. This study aimed to investigate the prevalence, antimicrobial resistance profile, and genomic characteristics of C. perfringens in pork production chains in Korea. The overall prevalence of C. perfringens was 23.6% (330/1397), with 48.8 (178/365), 16.6 (138/832), and 7.0% (14/200) in pig farms, slaughterhouses, and retail markets, respectively. Toxinotyping revealed 98.9% type A and 1.1% type C isolates. Among them, 29.1% carried the beta-2 toxin gene. Antimicrobial susceptibility tests identified 20 multi-drug resistant isolates, with the highest resistance against tetracycline (65.1%). Whole-genome sequencing further revealed 17 antimicrobial resistance and 12 virulence genes. Subsequent phylogenetic analysis identified three clonal clusters, two of which revealed a clonal relationship with human clinical isolates reported in China. The ST408 isolate from the retail pork meat, IJCP45, harboured the optrA gene in a plasmid and was identical to known optrA-carrying plasmids in C. perfringens from livestock in China, suggesting the introduction and dissemination of optrA by the transmission of a specific plasmid in east Asian countries. To our knowledge, this is the first comprehensive study of C. perfringens in the pork meat production system as an "One Health" approach. The study findings provide baseline data for the distribution and genetic characteristics of pig-associated C. perfringens in Korea and indicate the zoonotic transmission potential of C. perfringens from pigs to humans.

01 Jun 2025·JOURNAL OF HYDROLOGY

A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment

Author: Slosarczyk, Kinga ; Dabrowska, Dominika

The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.

9

News (Medical) associated with Penicillin G Sodium

27 Nov 2024

·www.echemi.com

Lyfius Pharma Invests 25 Billion Rupees to Build the World's Largest Penicillin G Factory

Lyfius Pharma Pvt Ltd, a manufacturer of penicillin G, announced the launch of its state-of-the-art manufacturing facility in Kakinada, Andhra Pradesh, on October 29th. The company has invested 25 billion rupees in the plant, which has an annual production capacity of 15,000 tons, under the Production Linked Incentive (PLI) scheme. The facility was inaugurated online by Prime Minister Narendra Modi, with the presence of several Indian ministers, including Chemicals and Fertilizers Minister Jagat Prakash Nadda, Labour and Employment Minister Mansukh Mandaviya, and others. Lyfius Pharma's director, MV Rama Krishna, highlighted the significance of the Pen-G factory's launch as a milestone in strengthening local production and reducing reliance on imported key drug components. The investment underscores the company's commitment to the government's vision of "Atmanirbhar Bharat" (Self-Reliant India), aiming to establish India as a global pharmaceutical manufacturing hub. The company expects commercial production to accelerate in the fiscal year 2025, enhancing domestic output of key starting materials (KSM), drug intermediates (DI), and active pharmaceutical ingredients (API). Lyfius Pharma, a subsidiary of Aurobindo Pharma, operates the advanced facility in Andhra Pradesh, which is one of India's largest fermentation-based antibiotic intermediate plants, featuring large-capacity fermenters and automated starch and glucose plants. The project feasibility report outlines the production of 2,000 tons/year of 7-ACA, 15,000 tons/year of penicillin G, 198,000 tons/year of glucose, and 4,200 tons/year of 6-APA, with co-line products including 1,800 tons/year of amoxicillin trihydrate (enzyme method) and 1,800 tons/year of ampicillin trihydrate (enzyme method). Aurobindo Pharma's Q2FY2025 financial results show an 8.0% year-over-year increase in revenue to 77.96 billion rupees, with an EBITDA of 19.54 billion rupees before research and development, a profit margin of 25.1%, and a net profit of 8.17 billion rupees, up 8.6%. The company's performance indicates positive growth trends, particularly in Europe and growth markets, despite a 22.8% decline in ARV (antiretroviral) business revenue. The API business maintained stable revenue at 11.56 billion rupees, contributing 14.8% to total revenue.

Financial Statement

02 Apr 2024

·www.pharmaindustrial-india.com

Aurobindo Pharma Expands Manufacturing Capabilities with Four New Facilities

Aurobindo Pharma Limited, a pharmaceutical company, has recently commissioned four state-of-the-art manufacturing facilities through its subsidiaries, each located strategically in Andhra Pradesh, India. Lyfius Pharma Private Limited, situated in the Kakinada SEZ area of Thondangi Mandal, Kakinada District, boasts an annual production capacity of 15,000 metric tons (MT) of Penicillin-G (Pen-G) and 1,80,000 MT of Glucose. With a market reach spanning captive use, domestic supply, and exports, Lyfius Pharma is poised to cater to diverse demands in the pharmaceutical sector. Similarly, Qule Pharma Private Limited, also located in the Kakinada SEZ area, will produce 6-Amino Penicillanic Acid (6-APA). The facility possesses a substantial annual production capacity of 3,600 MT. Moving on to Eugia Steriles Private Limited, based in Tadi Village, Parawada Mandal, Anakapalli District, the focus lies on the production of vials and ampoules. With an annual production capacity of 285 million units, Eugia Steriles primarily targets the export market, contributing to the global supply chain of pharmaceutical products. Lastly, Auroactive Pharma Private Limited, nestled in Sancham Village, Ranasthalam Mandal, Srikakulam District, focuses on the production of granulated products ready for compression. With an annual production capacity of 13,200 MT, this facility serves a diverse market encompassing captive use, domestic supply, and exports. These facilities have commenced commercial production of their respective products and have already made commercial sales to customers based on received purchase orders. It is anticipated that the revenues and profitability of these entities will experience growth over time as they ramp up their operations and cater to both domestic and international markets.

02 Apr 2024

·www.pharmaindustrial-india.com

Aurobindo Pharma Expands Manufacturing Capabilities with Four New Facilities

Aurobindo Pharma Limited, a pharmaceutical company, has recently commissioned four state-of-the-art manufacturing facilities through its subsidiaries, each located strategically in Andhra Pradesh, India. Lyfius Pharma Private Limited, situated in the Kakinada SEZ area of Thondangi Mandal, Kakinada District, boasts an annual production capacity of 15,000 metric tons (MT) of Penicillin-G (Pen-G) and 1,80,000 MT of Glucose. With a market reach spanning captive use, domestic supply, and exports, Lyfius Pharma is poised to cater to diverse demands in the pharmaceutical sector. Similarly, Qule Pharma Private Limited, also located in the Kakinada SEZ area, will produce 6-Amino Penicillanic Acid (6-APA). The facility possesses a substantial annual production capacity of 3,600 MT. Moving on to Eugia Steriles Private Limited, based in Tadi Village, Parawada Mandal, Anakapalli District, the focus lies on the production of vials and ampoules. With an annual production capacity of 285 million units, Eugia Steriles primarily targets the export market, contributing to the global supply chain of pharmaceutical products. Lastly, Auroactive Pharma Private Limited, nestled in Sancham Village, Ranasthalam Mandal, Srikakulam District, focuses on the production of granulated products ready for compression. With an annual production capacity of 13,200 MT, this facility serves a diverse market encompassing captive use, domestic supply, and exports. These facilities have commenced commercial production of their respective products and have already made commercial sales to customers based on received purchase orders. It is anticipated that the revenues and profitability of these entities will experience growth over time as they ramp up their operations and cater to both domestic and international markets.

100 Deals associated with Penicillin G Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D05408	-	S01AA14 J01CE01	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Endocarditis, Bacterial	Australia	Seqirus Pty Ltd.	04 Nov 1991
Sepsis	Australia	Seqirus Pty Ltd.	04 Nov 1991
Streptococcal Infections	Australia	Seqirus Pty Ltd.	04 Nov 1991
Surgical Wound Infection	Australia	Seqirus Pty Ltd.	04 Nov 1991
Syphilis	Australia	Seqirus Pty Ltd.	04 Nov 1991
Bacterial Infections	-	Pfizer Inc.	01 Jan 1942

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAAAI2023	Not Applicable	-	-	Amoxicillin challenge	brydzkmmgg(crjgynfcpr) = mofutqlhzh mwahueuwgz (rwezlagpjg )	-	01 Feb 2023
AAAAI2023	Not Applicable	Allergy to penicillin	-	Penicillin Skin Testing	yhqwuocukc(hyhapstwgm) = amzwqimvin fgvbwsutik (jwauleaojf ) View more	-	01 Feb 2023
				Penicillin (2-Step Direct Challenge)	zqbcvanccb(vnusvrvzct) = sgamrgfmgd hmwymfxebu (ayuqoidzvm ) View more
NCT01255670 (CTgov)	Not Applicable	Peritonsillar Abscess	200	metronidazole+penicillin (Penicillin and Metronidazole)	acubffvrmf = vbdaikvcri pwbnjphvsc (untemubicq, sxukxubtmf - yoocnnptao) View more	-	11 May 2021
				metronidazole+penicillin (Penicillin and Placebo)	acubffvrmf = qtafmpdjgc pwbnjphvsc (untemubicq, moynfxluxt - rjybkndtgm) View more
AAAAI2021	Not Applicable	-	452	penicillin (PST alone)	pptkwjqohm(ehjwurujyk) = abidkhbldm ckcpnnzwbo (pnqqkjryvj )	Positive	01 Feb 2021
				penicillin (PST and oral drug challenge)	pptkwjqohm(ehjwurujyk) = aoslwlwujy ckcpnnzwbo (pnqqkjryvj )
EHA2019	Not Applicable	Anemia, Sickle Cell	133	PENICILLIN PROPHYLAXIS (Patients on antibiotic prophylaxis)	wqwnawyrog(dnxvcgcpcm) = njyilslfav tprzulqlcp (djwebkfnik )	-	14 Jun 2019
				PENICILLIN PROPHYLAXIS (Patients not on antibiotic prophylaxis)	cozvjhtudz(kekibaaojp) = bnkkiswwrt kunpygmvzj (rnyddhbmxx )
AAAAI2019	Not Applicable	-	-	Oral clindamycin	xetbbdobul(lfmolutbbt) = cqxzoyvoyb wnranqvyuw (iderlocgww, 1in685 - 460)	-	01 Feb 2019
				Parenteral clindamycin	xetbbdobul(lfmolutbbt) = qklspxnvpt wnranqvyuw (iderlocgww, 1in685 - 460)
ASN2013	Not Applicable	Syphilis \| Glomerulonephritis HIV \| RPR \| Treponema pallidum particle agglutination assay	1	Penicillin	ecyzorvwca(fgsuzphhwy) = ccsbeytzaq qmpaucperh (ihgqjuqfvb )	Positive	05 Nov 2013
AAAAI2005	Not Applicable	Streptococcal Infections \| Allergy to penicillin penicillin allergy	47	Penicillin (PST negative)	infcpluzus(ckwfioyvkq) = There were 2 delayed onset rashes associated with peripartum penicillins nxzfdmxndq (xnzpksbkmd ) View more	-	21 Mar 2005
IAS2004	Not Applicable	Neurosyphilis	31	intravenous Penicillin G (HIV-positive patients with serological examined SI)	qwpfzqriqq(ohogdtdcjw) = kqeltvxzzy syolflikat (efiovekcuj ) View more	-	01 Jan 2004
Pubmed \| J Antimicrob Chemother	Not Applicable	-	-	Benzylpenicillin	zzvhtvflev(vvtyuxobos) = cvavzejoua dkbvctqdbt (axcjnamajc )	-	01 Jan 1988
				Imipenem/cilastatin	zzvhtvflev(vvtyuxobos) = pramoydtbm dkbvctqdbt (axcjnamajc )